
T: +44 (0) 7919 211836

Sample Presentations
​
Here are some sample presentations. In most cases the work has subsequently been published in peer-reviewed journals.
On this page you can find a full list of citations.
Immunotherapy Trial Design
​What are the implications for trial design, sizing, analysis and interpretation if the treatment effect is delayed
​
​
​
Adaptive Trial Design
​Experience and learning from one of the first adaptive trials performed in oncology
​
​
​
Biomarkers and Subgroups
​How to establish which patients benefit most from therapy
​
​
​
Progression Free Survival
​How to best design and analyse your trial when using PFS
​
​
​
Phase II trial design
​The benefits of randomisation even with small patient numbers
​
​
​
Publications
​
Manuscripts published in peer review journals on trial design and methodology in a regulatory setting

Model free audit methodology for bias evaluation
of tumour progression in oncology.
Stone A, Macpherson E, Smith A,
Jennison C Pharmaceutical Statistics 2015 14:455-463
​
When is a seamless study desirable?
Case studies from different pharmaceutical sponsors.
Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. Pharmaceutical Statistics 2014 13: 229-237
Can a treatment be licensed on the basis of post
treatment predictive biomarkers?
Stone A, Schmitt N. Pharmaceutical Statistics 2014 13: 214-221
Strong control over multiple endpoints: are we adding value to the assessment of medicines?
Stone A, Chuang-Stein C. Pharmaceutical Statistics
2013 12: 189-191
Missing data and censoring in the analysis of progression free survival in oncology clinical trials.
Denne J, Stone A, Bailey-Iacona R, Chen T. J
Biopharmaceutical Statistics 2013 23: 951-970
Attenuation of treatment effect due to measurement variability in assessment of progression-free survival.
Hong S, Schmitt N, Stone A, Denne J.
Pharmaceutical Statistics 2012 11: 394-402